ClinicalTrials.Veeva

Menu

REFINE-CAC Protocol: Risk Evaluation With AI-CPA + HCS For Patients IN Whom Calcium is confirmEd to Improve Coronary Artery Disease Care

HeartFlow logo

HeartFlow

Status

Not yet enrolling

Conditions

CAD - Coronary Artery Disease

Treatments

Device: Heartflow Analysis

Study type

Interventional

Funder types

Industry

Identifiers

NCT07853716
CP-913-001

Details and patient eligibility

About

REFINE-CAC is a prospective, multi-center trial assessing the management of asymptomatic participants with CAC scores 1-299 Agatston units or incidental CAC findings on chest computed tomography (CT), all of whom will undergo CCTA and are blinded to the coronary anatomy (e.g., % stenosis). The trial includes a randomized, controlled pathway and a single arm, observational registry pathway.

Full description

The primary objective of the REFINE-CAC trial is to assess change in lipid lowering therapy over time in asymptomatic participants with coronary artery calcium (CAC) findings who will undergo a blinded coronary computed tomographic angiography (CCTA) and are randomly assigned to either the test arm or the usual care arm.

Enrollment

500 estimated patients

Sex

All

Ages

40 to 79 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Calcium score between 1-299 between 3-6 months prior to Day 0 or incidental CAC findings on a chest CT between 3 to 6 months prior to Day 0
  2. Men ≥40 and ≤79, Women ≥45 and ≤79
  3. Patients who do not have symptoms suggestive of CAD
  4. Visible plaque on CCTA
  5. No other clinical CCTA subsequent to CAC findings but prior to screening
  6. No prior history of atherosclerotic cardiovascular disease (ASCVD)
  7. Acceptable CCTA quality per Heartflow acceptance criteria
  8. eGFR >45 mL/min per most recent measurement within 90 days
  9. Willingness to comply with all aspects of the protocol including research CCTAs, lab draws, medication adherence assessments, attending all study visits, and the ability to comply with prescribed medications
  10. For participants of childbearing potential (those who have not been surgically sterilized), a pregnancy test must be performed with negative results known within 7 days prior to randomization
  11. Ability to provide informed consent

Exclusion criteria

  1. Symptoms suggestive of CAD (e.g. stable angina)
  2. On PCSK9 targeted therapy (e.g. evolocumab, alirocumab, inclisiran, or enlicitide)
  3. Reduced left ventricular ejection fraction (LVEF) <35%, if known
  4. Prior history of ASCVD
  5. Prior coronary artery bypass graft (CABG)
  6. Prior percutaneous coronary intervention (PCI)
  7. Life expectancy less than 2 years due to non-CV comorbidities
  8. Enrolled in an investigational trial that involves a non-approved cardiac drug or device
  9. Previously evaluated with and/or in a trial which includes AI-CPA
  10. Any condition that might interfere with trial procedures or follow up visits
  11. LDL-C <70 mg/dL at baseline lab draw
  12. Active chemotherapy and/or radiation

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

500 participants in 3 patient groups

Usual Care Arm
No Intervention group
Unblinded Test Arm
Experimental group
Treatment:
Device: Heartflow Analysis
Unblinded Registry Arm
Other group
Treatment:
Device: Heartflow Analysis

Trial contacts and locations

1

Loading...

Central trial contact

Blair Holman; Whitney Huey

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems